Effect of simvastatin on monocyte CX3CR1 expression in patients with acute coronary syndrome.
- Author:
Dan-dan PENG
1
;
Zhi-liang LI
Author Information
- Publication Type:Journal Article
- MeSH: Acute Coronary Syndrome; blood; drug therapy; CX3C Chemokine Receptor 1; Female; Gene Expression; drug effects; Humans; Hypolipidemic Agents; therapeutic use; Male; Monocytes; drug effects; metabolism; Receptors, Chemokine; genetics; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; therapeutic use
- From: Journal of Southern Medical University 2008;28(3):475-477
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of simvastatin on expression of CX3CR1 in the monocytes in patients with acute coronary syndrome and investigate the non-lipid mechanisms of statins against atherosclerosis.
METHODSThe expression of CX3CR1 in the monocytes was measured by quantitative real-time RT-PCR in 63 patients with acute coronary syndrome confirmed by coronary arteriography after treatment with simvastatin at 10(-7) approximately 10(-5) mol/L for 4, 8 and 12 h, respectively.
RESULTSCX3CR1 expression in the monocytes treated with different concentrations of simvastatin was significantly lower than that in the control cells (P<0.05), and the expression in the cells treated with the agent for different time lengths was also significantly lower than that in the control cells (P<0.01).
CONCLUSIONSimvastatin can reduce CX3CR1 expression in the monocytes of the patients with acute coronary syndrome in a concentration- and time-dependent manner, so as to reduce the inflammation and stabilize the vascular plaques.
